World Journal of
Pharmaceutical and Life Sciences

INVITRO EVALUATION OF ISONIAZID AND ITS DERIVATIVE (ISONIAZID ALPHA-KETOGLUTARIC ACID) FOR THE TREATMENT OF TUBERCULOSIS

Saniya Begum* and Dr. Syed Ahmed Hussain

ABSTRACT

Aim: This study aimed to investigate the cytotoxic and anti-angiogenic effects of Isoniazid alpha-ketoglutaric acid on colorectal TB HT-29 cells and human umbilical vein endothelial cells (HUVECs). Objective: The primary objective was to evaluate the impact of Isoniazid alpha-ketoglutaric acid on cell proliferation, tube formation, and the expression of key proteins related to angiogenesis, namely NF-κB and VEGF-A. Research: Using the MTT assay, we assessed the viability of HT-29 and HUVEC cells after treatment with various concentrations of Isoniazid alpha-ketoglutaric acid. The results indicated a significant reduction in cell proliferation in both cell lines. The Tubulogenesis assay showed that Isoniazid alpha-ketoglutaric acid inhibited the formation of tubular structures in HUVECs. Indirect Immunofluorescence and Western Blot analyses demonstrated decreased expression levels of NF-κB and VEGF-A in HT-29 cells and VEGFR-2 in HUVECs following treatment. Conclusion: Isoniazid alpha-ketoglutaric acid exhibits significant antiTB properties by reducing cell viability and inhibiting angiogenesis. The downregulation of crucial angiogenic factors highlights its potential as a therapeutic agent in colorectal TB treatment, warranting further studies to explore its clinical applications.

[Full Text Article]   [Download Certificate]